| Patient | Marcus Aurelius |
|---|---|
| Date of birth | 1973-04-25 |
| Identifiers | MRN HR-AC004-SYN; SSN (made up) 000-04-1213 |
| Document date | 2026-11-01 |
| Author | Octavia Ashworth-Nnamdi, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for chronic epigastric and lower chest pain after meals, poor appetite and poor sleep: cardiac assessment first, review of an opium-containing remedy, and gastroenterology referral for endoscopy. Concerns: He has had pain in his chest and stomach after meals for more than a year and wants to know whether his heart is sound; He sleeps badly and is tired, and must stay clear-headed for his work; He has taken the herbal paste for years and does not want to be judged for it, or made to stop it before he is ready. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Opium-containing compounded herbal paste (an electuary of honey, many herbs and poppy, from an overseas supplier; not prescribed and not regulated, so its morphine content is unknown), about a pea-sized amount (roughly 0.5 g) by mouth at bedtime most nights for about six years, and now and then in the morning before a long day | About 0.5 g at bedtime most nights; occasionally a second amount in the morning | Oral route | 2020-05-01 to 2026-06-06 | completed | S |
| Calcium carbonate 500 mg chewable tablet, one or two tablets as needed for heartburn, no more than six a day, until the endoscopy | One or two tablets as needed, at least four hours apart; no more than six a day | Oral route | 2026-05-12 to 2026-05-19 | completed | S |
| Polyethylene glycol 3350 powder, 17 g dissolved in a glass of water by mouth once daily as needed for constipation | 17 g once daily as needed | Oral route | 2026-05-12 | active | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeated in 2 to 3 minutes in the other nostril if there is no response; call 911 | One spray for suspected overdose; repeat every 2 to 3 minutes if needed | Nasal route | 2026-05-12 | active | S |
| Omeprazole 20 mg delayed-release capsule, one capsule by mouth 30 to 60 minutes before breakfast for eight weeks, for erosive esophagitis | One capsule each morning before breakfast for eight weeks | Oral route | 2026-05-19 to 2026-07-14 | completed | S |
| Omeprazole 20 mg delayed-release capsule, one capsule by mouth before breakfast on days after heartburn returns (on-demand therapy after the eight-week course) | One capsule on a day with heartburn; no more than one a day | Oral route | 2026-07-14 | active | S |
| Opium-containing compounded herbal paste (unregulated, strength unknown), about 0.5 g by mouth at bedtime on alternate nights, a reduction he chose and made himself | About 0.5 g at bedtime every other night | Oral route | 2026-06-06 to 2026-07-28 | completed | S |
| Opium-containing compounded herbal paste (unregulated, strength unknown), a smaller amount, about 0.3 g, by mouth at bedtime on about two nights a week, a further reduction he chose | About 0.3 g at bedtime on about two nights a week | Oral route | 2026-07-28 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth every six hours as needed for fever or aches, no more than 3 g a day | One or two tablets every six hours as needed; no more than six a day | Oral route | 2026-07-07 to 2026-07-28 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Twelve-lead electrocardiogram at intake: sinus rhythm 76, normal intervals, no ST or T-wave changes, no Q waves | 2026-05-12 to 2026-05-12 | completed | S |
| CT coronary angiography with coronary calcium scoring (prospectively ECG-gated): coronary calcium score 0, no plaque or stenosis (CAD-RADS 0) | 2026-05-19 to 2026-05-19 | completed | S |
| Upper endoscopy (esophagogastroduodenoscopy) under moderate sedation | 2026-05-19 to 2026-05-19 | completed | S |
| Gastric biopsies (two antrum, one incisura, two body; updated Sydney protocol) with a rapid urease test | 2026-05-19 to 2026-05-19 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-07-28 to 2026-07-28 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-07-28 | Pneumococcal conjugate vaccine, 20-valent (PCV20), single dose for an adult aged 50 or older | completed | S |
| 2026-07-28 | Recombinant zoster vaccine (RZV), dose 1 of 2 | completed | S |
| 2026-07-28 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 2026-08-25 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| In boyhood (year not recorded) | As a boy, study so hard that it impaired his health (no illness named) | D (CLM-0015) |
| Before the first book of the Meditations, written about 171 to 175 CE | Blood-spitting and giddiness, for which he credits remedies shown to him in dreams (cause not recorded in the cited source) | D (CLM-0008) |
| During his reign (year not recorded) | Frail in body; stomach and chest 'in bad condition'; ate little and only at night; took theriac daily (cause not recorded in the cited source) | D (CLM-0006, CLM-0009) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He has had pain in his chest and stomach after meals for more than a year and wants to know whether his heart is sound | active | S |
| He sleeps badly and is tired, and must stay clear-headed for his work | active | S |
| He has taken the herbal paste for years and does not want to be judged for it, or made to stop it before he is ready | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 14.6 on 2026-05-12; MCV [Entitic mean volume] in Red Blood Cells by Automated count 90 on 2026-05-12; Leukocytes [#/volume] in Blood by Automated count 6.2 on 2026-05-12; Platelets [#/volume] in Blood by Automated count 238 on 2026-05-12; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-05-12; Potassium [Moles/volume] in Serum or Plasma 4.3 on 2026-05-12; Urea nitrogen [Mass/volume] in Serum or Plasma 14 on 2026-05-12; Creatinine [Mass/volume] in Serum or Plasma 0.95 on 2026-05-12; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 96 on 2026-05-12; Glucose [Mass/volume] in Serum or Plasma 92 on 2026-05-12; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 2026-05-12; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 2026-05-12; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 72 on 2026-05-12; Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 on 2026-05-12; Albumin [Mass/volume] in Serum or Plasma 4.1 on 2026-05-12; Lipase [Enzymatic activity/volume] in Serum or Plasma 32 on 2026-05-12; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 2026-05-12; Cholesterol [Mass/volume] in Serum or Plasma 205 on 2026-05-12; Cholesterol in HDL [Mass/volume] in Serum or Plasma 48 on 2026-05-12; Triglyceride [Mass/volume] in Serum or Plasma 120 on 2026-05-12; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 133 on 2026-05-12; Lipoprotein a [Moles/volume] in Serum or Plasma 38 on 2026-05-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-08-25; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 3 on 2026-08-25; Total score [AUDIT-C] 2 on 2026-07-28; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-07-28 [S]
Strengths and supports: Family: has children; his family lives far from the field site. Supports: a few trusted colleagues and his own discipline [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Burning and pressing pain in the upper abdomen and lower chest after meals, for more than a year and worse over three months, with poor appetite, waking at night with pain and a sour taste, and a 3 kg weight loss; not brought on by exertion; normal ECG; cardiac and peptic causes to be excluded | resolved | confirmed | R10.13 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis at endoscopy; its pattern echoes the stomach and chest complaints and the pain with food that Dio describes (D). |
| Gastroesophageal reflux disease with erosive esophagitis, Los Angeles grade B, and a 2 cm sliding hiatal hernia; Helicobacter pylori negative on biopsy; coronary disease excluded by CT coronary angiography; synthetic modern diagnosis for his documented stomach and chest complaints | active | confirmed | K21.00 | S — Synthetic modern diagnosis; the cause of his real complaints is unknown and no historical diagnosis is made. |
| Daily use of an unregulated opium-containing herbal remedy for about six years, for stomach pain and sleep; opioid use disorder criteria not met (one DSM-5-TR criterion, restlessness and poor sleep when he stopped it); expected physiological dependence; constipation and possibly slowed gastric emptying from the opioid | active | confirmed | F11.90 | S — Synthetic modern finding anchored to the theriac he took (D); no opioid use disorder or addiction is attributed to him (the claim is disputed, R). |
| Chronic insomnia disorder for more than a year, with waking from night pain and trouble returning to sleep; Insomnia Severity Index 17 (moderate) | active | confirmed | G47.00 | S — Synthetic modern finding anchored to Galen's account of his sleeplessness without the poppy juice (D, possible). |
| Sustained strain of command: leads a large organization through a long field assignment far from home, with long days and little rest | active | confirmed | Z56.6 | S — Synthetic work strain anchored to his documented years on campaign (D). |
| Constipation from the opioid in his remedy: hard stools every two or three days | active | confirmed | K59.03 | S — Synthetic finding at intake. |
| COVID-19, mild (rapid antigen test positive), without breathlessness or low oxygen; antiviral treatment offered and declined; resolved | resolved | confirmed | U07.1 | S — Synthetic intercurrent illness; not a claim about the Antonine Plague or about any illness in his lifetime. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-12 | Hemoglobin [Mass/volume] in Blood | 14.6 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 2026-05-12 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 90 | fL | 80-100 fL | Normal | S |
| 2026-05-12 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-12 | Platelets [#/volume] in Blood by Automated count | 238 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-05-12 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-12 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-12 | Urea nitrogen [Mass/volume] in Serum or Plasma | 14 | mg/dL | 7-20 mg/dL | Normal | S |
| 2026-05-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.95 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-05-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 96 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-12 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-139 mg/dL | Normal | S |
| 2026-05-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-55 U/L | Normal | S |
| 2026-05-12 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-48 U/L | Normal | S |
| 2026-05-12 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 72 | U/L | 40-129 U/L | Normal | S |
| 2026-05-12 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-05-12 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-05-12 | Lipase [Enzymatic activity/volume] in Serum or Plasma | 32 | U/L | 13-60 U/L | Normal | S |
| 2026-05-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-05-12 | Cholesterol [Mass/volume] in Serum or Plasma | 205 | mg/dL | <=199 mg/dL | High | S |
| 2026-05-12 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 48 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-05-12 | Triglyceride [Mass/volume] in Serum or Plasma | 120 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-05-12 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 133 | mg/dL | <=129 mg/dL | High | S |
| 2026-05-12 | Lipoprotein a [Moles/volume] in Serum or Plasma | 38 | nmol/L | 125 nmol/L or more adds to cardiovascular risk | Normal | S |
| 2026-05-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-05-12 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 2026-05-12 | Total score [AUDIT-C] | 3 | {score} | S | ||
| 2026-06-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-08-25 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-08-25 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | {score} | S | ||
| 2026-07-28 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-07-28 | Total score [AUDIT-C] | 2 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-12 | Body height | 172 | cm | S |
| 2026-05-12 | Body weight | 63 | kg | S |
| 2026-05-12 | Body mass index (BMI) [Ratio] | 21.3 | kg/m2 | S |
| 2026-05-12 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-05-12 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-05-12 | Heart rate | 76 | /min | S |
| 2026-05-12 | Respiratory rate | 14 | /min | S |
| 2026-05-12 | Body temperature | 36.6 | Cel | S |
| 2026-05-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-19 | Body height | 172 | cm | S |
| 2026-05-19 | Body weight | 63.2 | kg | S |
| 2026-05-19 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 2026-05-19 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-05-19 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-05-19 | Heart rate | 74 | /min | S |
| 2026-05-19 | Respiratory rate | 14 | /min | S |
| 2026-05-19 | Body temperature | 36.5 | Cel | S |
| 2026-05-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-06-16 | Body height | 172 | cm | S |
| 2026-06-16 | Body weight | 64 | kg | S |
| 2026-06-16 | Body mass index (BMI) [Ratio] | 21.6 | kg/m2 | S |
| 2026-06-16 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-06-16 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-06-16 | Heart rate | 72 | /min | S |
| 2026-06-16 | Respiratory rate | 14 | /min | S |
| 2026-06-16 | Body temperature | 36.6 | Cel | S |
| 2026-06-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-25 | Body height | 172 | cm | S |
| 2026-08-25 | Body weight | 65 | kg | S |
| 2026-08-25 | Body mass index (BMI) [Ratio] | 22 | kg/m2 | S |
| 2026-08-25 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-08-25 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-25 | Heart rate | 70 | /min | S |
| 2026-08-25 | Respiratory rate | 14 | /min | S |
| 2026-08-25 | Body temperature | 36.6 | Cel | S |
| 2026-08-25 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-07 | Body height | 172 | cm | S |
| 2026-07-07 | Body weight | 63.6 | kg | S |
| 2026-07-07 | Body mass index (BMI) [Ratio] | 21.5 | kg/m2 | S |
| 2026-07-07 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-07-07 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-07-07 | Heart rate | 94 | /min | S |
| 2026-07-07 | Respiratory rate | 16 | /min | S |
| 2026-07-07 | Body temperature | 38.3 | Cel | S |
| 2026-07-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-07-28 | Body height | 172 | cm | S |
| 2026-07-28 | Body weight | 64.4 | kg | S |
| 2026-07-28 | Body mass index (BMI) [Ratio] | 21.8 | kg/m2 | S |
| 2026-07-28 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-07-28 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-07-28 | Heart rate | 70 | /min | S |
| 2026-07-28 | Respiratory rate | 14 | /min | S |
| 2026-07-28 | Body temperature | 36.6 | Cel | S |
| 2026-07-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-05-12 | New patient visit for chronic epigastric and lower chest pain after meals, poor appetite and poor sleep: cardiac assessment first, review of an opium-containing remedy, and gastroenterology referral for endoscopy | finished | S |
| 2026-05-19 | Gastroenterology consultation with upper endoscopy and biopsy, review of the CT coronary angiogram, diagnosis of erosive esophagitis, and start of omeprazole | finished | S |
| 2026-06-16 | Five-week review: reflux symptoms on omeprazole, biopsy results, sleep therapy, and the remedy | finished | S |
| 2026-08-25 | Fifteen-week review after the eight-week omeprazole course: on-demand therapy, sleep, the remedy, and mood | finished | S |
| 2026-07-07 | Same-day sick visit for mild COVID-19 while taking an opium-containing remedy | finished | S |
| 2026-07-28 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Cardiac assessment first: twelve-lead ECG today; a structured estimate of the chance of coronary disease; no troponin, because the pain is chronic and there is no acute episode; CT coronary angiography within a week, chosen over stress testing because it excludes both obstructive and non-obstructive plaque and informs the cholesterol decision; call 911 for chest pain at rest lasting more than a few minutes, or pain with breathlessness, sweating or fainting | completed | GL-AHA-CP-2021, GL-CMID-2026 | S |
| Gastroenterology consultation for upper endoscopy within one week, with gastric biopsies for Helicobacter pylori, to find the cause of the chest and epigastric pain after the cardiac assessment and to advise on treatment; no acid-suppressing drug before the endoscopy, with an antacid as needed | completed | GL-ACG-GERD-2022, GL-ACG-DYS-2017, GL-ACG-HP-2024 | S |
| Respectful review of the opium-containing remedy: what it is, why he takes it, and what it does for him; a DSM-5-TR assessment; a prescription drug monitoring program check; a urine drug test with his consent, explained as part of care; naloxone at home; no alcohol, sleep medicines or other sedatives on the same night; never more than his usual amount; stored closed and out of reach; how opioids slow the gut; no forced or abrupt taper, and any reduction his own choice, made slowly; reviewed at every visit, with the 988 Suicide & Crisis Lifeline | completed | GL-CDC-OPIOID-2022 | S |
| Chronic insomnia: cognitive behavioral therapy for insomnia (CBT-I) with the clinic's behavioral sleep clinician, six sessions, with a sleep diary, sleep restriction, stimulus control and work on racing thoughts at night; Insomnia Severity Index at intake and at each review; no hypnotic or sedating antihistamine, which would add to the opioid | completed | GL-AASM-INS-2021, GL-ACP-INS-2016 | S |
| Strain of command and mood: PHQ-9 and GAD-7 at intake and at follow-up; protected time for meals and sleep, decisions delegated after a set hour, and his evening writing kept; counselling if scores rise | completed | GL-USPSTF-DEP-2023 | S |
| Constipation: polyethylene glycol as needed, fluids and fiber; review as the remedy changes | completed | GL-CDC-OPIOID-2022 | S |
| Reflux esophagitis: omeprazole 20 mg 30 to 60 minutes before breakfast for eight weeks, then a trial off with omeprazole on demand; the evening meal at least three hours before lying down, the head of the bed raised, and less wine at night; no repeat endoscopy for grade B esophagitis; esophageal manometry and reflux monitoring off therapy if symptoms persist or swallowing becomes difficult | completed | GL-ACG-GERD-2022 | S |
| Mild COVID-19: rest, fluids and acetaminophen; honey for cough; no codeine or dextromethorphan cough medicine, sedating antihistamine or sleep aid while he takes the opium-containing remedy, and no more of the remedy than usual; naloxone at hand; antiviral treatment offered and declined after a shared decision; stay away from others until fever-free for 24 hours without medicine and improving, then added precautions for five days; call 911 for breathlessness, chest pain, confusion or blue lips, and return for oxygen saturation below 94% on a home oximeter | completed | GL-CDC-RESP-2024, GL-CDC-COVIDTX-2025, GL-IDSA-COVID, GL-CDC-OPIOID-2022 | S |
| Colorectal cancer screening: colonoscopy ordered for the first quiet stretch of his assignment, with a split-dose bowel preparation and two extra days of polyethylene glycol beforehand because the opioid slows the bowel, and no remedy the night before; fecal immunochemical testing each year if he prefers not to have colonoscopy | completed | GL-USPSTF-CRC-2021 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| A cardiac cause of the chest pain excluded within two weeks | 2026-05-19 | completed | Normal ECG at intake; CT coronary angiography one week later: calcium score 0 and no plaque | S |
| Chest and stomach pain after meals controlled, with appetite and weight returning | 2026-08-25 | completed | Pain gone on omeprazole; occasional mild heartburn after late meals on on-demand therapy; weight up 2 kg | S |
| Insomnia Severity Index below 8 within four months | 2026-08-25 | completed | Insomnia Severity Index 7 after six sessions of CBT-I | S |
| The remedy used as safely as he can: naloxone at home, never with alcohol or sleep medicines, and decisions about it his own | 2026-08-25 | active | Naloxone at home; no alcohol on nights he takes it; by his own choice now about two nights a week | S |
Structured synthetic safety assessment on 2026-05-12: current ideation absent, intent absent, plan absent. Outpatient care; the 988 Suicide & Crisis Lifeline; naloxone at home; the remedy kept in a closed container out of others' reach and never taken with alcohol or sleep medicines; review at every visit [S]